Put companies on watchlist
Redcare Pharmacy N.V.
ISIN: NL0012044747
WKN: A2AR94
Curious about what AI knows about Redcare Pharmacy? Just one click more
More AI Integrations
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

Redcare Pharmacy N.V. · ISIN: NL0012044747 · EQS - adhoc news (121 News)
Country: Netherlands · Primary market: Netherlands · EQS NID: 1887349
23 April 2024 03:56PM

Redcare Pharmacy’s eHealth-CardLink solution approved by gematik today.


EQS-Ad-hoc: Redcare Pharmacy N.V. / Key word(s): Regulatory Approval
Redcare Pharmacy’s eHealth-CardLink solution approved by gematik today.

23-Apr-2024 / 15:56 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Redcare Pharmacy’s eHealth-CardLink solution approved by gematik today.

Today, Redcare Pharmacy has received approval to implement its eHealth-CardLink solution from the German national agency for digital medicine, gematik. This will enable Redcare Pharmacy to offer patients in Germany a user-friendly method to redeem e-prescriptions by using their electronic health card and their mobile phone.  

The eHealth-CardLink solution is expected to be available in Redcare Pharmacy´s German Shop Apotheke app by early May.

 

 

 




Contact:
rikutis consulting
Thomas Schnorrenberg
Cel: +49 151 46 53 13 17
E-Mail: presse@shop-apotheke.com


End of Inside Information

23-Apr-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: Redcare Pharmacy N.V.
Erik de Rodeweg 11-13
5975 WD Sevenum
Netherlands
Phone: 0800 - 200 800 300
Fax: 0800 - 90 70 90 20
E-mail: investors@redcare-pharmacy.com
Internet: www.redcare-pharmacy.com
ISIN: NL0012044747, DE000A19Y072
WKN: A2AR94, A19Y072
Indices: MDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1887349

 
End of Announcement EQS News Service

1887349  23-Apr-2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1887349&application_name=news&site_id=boersengefluester~~~ace3d64b-2049-452a-8d18-fbc8044c4b5f
Visual performance / price development - Redcare Pharmacy N.V.
Smart analysis and research tools can be found here.
MIC: XETR
Power-Shortcuts

Redcare Pharmacy NV

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2025
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.